Evidence map›Paper›PMID 35182841›Full record

SynthesisThe International journal on drug policy2022

Medication for opioid use disorder in the Arab World: A systematic review.

Jude Alawa, Muzzammil Muhammad, Maryam Kazemitabar, Daniel J Bromberg, Danilo Garcia, Kaveh Khoshnood, Lilian Ghandour

Abstract readSystematic Review
In one paragraph

Synthesis in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jude AlawaStanford University School of Medicine, 291 Campus Drive, Stanford, CA 94305, United States.
Muzzammil MuhammadYale University School of Medicine, 333 Cedar St, New Haven, CT 06510, United States.
Maryam KazemitabarYale University School of Public Health, 60 College St, New Haven, CT 06510, United States.
Daniel J BrombergYale University School of Public Health, 60 College St, New Haven, CT 06510, United States.
Danilo GarciaCentre for Ethics, Law and Mental Health (CELAM), University of Gothenburg, Box 100, 405 30 Gothenburg, Gothenburg, Sweden; Department of Behavioral Sciences and Learning, Linköping University, SE 581 83, Linköping, Sweden.
Kaveh KhoshnoodYale University School of Public Health, 60 College St, New Haven, CT 06510, United States.
Lilian GhandourDepartment of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Van Dyck Building, PO Box 11-0236, Riad El-Solh Beirut, 1107 2020, Lebanon. Electronic address: lg01@aub.edu.lb.

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
INTERDISCIPLINARY HIV PREVENTION TRAINING PROGRAMT32MH020031 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 1999 to 2026
$12.1M
Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in UkraineF31DA054861 · NIDA · YALE UNIVERSITY · PI BROMBERG, DANIEL J · 2021 to 2023
$94k
FIC NIH HHS D43 TW010540NIDA NIH HHS F31 DA054861NIMH NIH HHS T32 MH020031
6 · The paper itself

Abstract

backgroundOpioid use disorder (OUD) is a global public health concern. The standard of care for OUD involves treatment using medications such as buprenorphine, methadone, or naltrexone. No known review exists to assess the contextual factors associated with medication for opioid use disorder (MOUD) in the Arab World. This systematic review serves as an implementation science study to address this research gap and improve the uptake of MOUD in the Arab World.

methodsSystematic searches of Medline, PsycINFO, and EMBASE, and a citation analysis, were used to identify peer-reviewed articles with original data on MOUD in the Arab World. Quality assessment was conducted using the CASP appraisal tools, and main findings were extracted and coded according to the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.

results652 research articles were identified, and 10 met inclusion criteria for final review. Four studies considered health-systems aspects of MOUD administration, such as cost-effectiveness, the motivations for and impact of national MOUD policies, the types of social, political, and scientific advocacy that led to the adoption of MOUD in Arab countries, and the challenges limiting its wide-scale adoption in the Arab World. Six papers considered MOUD at individual and group patient levels by evaluating patient quality of life, addiction severity, patient satisfaction, and patient perspectives on opioid agonist therapy.

conclusionDespite financial and geographic barriers that limit access to MOUD in the Arab World, this review found MOUD to be cost-effective and associated with positive health outcomes for OUD patients in the Arab World. MOUD can be successfully established and scaled to the national level in the Arab context, and strong coalitions of health practitioners can lobby to establish MOUD programs in Arab countries. Still, the relative novelty of MOUD in this context precludes an abundance of research to address its long-term delivery in the Arab World.

Indexed as

BuprenorphineOpioid-Related DisordersAnalgesics, OpioidArab WorldHumansMethadoneOpiate Substitution TreatmentPharmaceutical PreparationsQuality of LifeAnalgesics, OpioidBuprenorphineMethadonePharmaceutical PreparationsArab WorldImplementation scienceMedication for opioid use disorderOpioid agonist therapyOpioid use disorderSubstance use

Identifiers

PMID35182841
PMCPMC9851143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.